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ARTICLE
NOTCH signaling speciﬁes arterial-type deﬁnitive
hemogenic endothelium from human pluripotent
stem cells
Gene I. Uenishi1,2, Ho Sun Jung1, Akhilesh Kumar 1, Mi Ae Park 1, Brandon K. Hadland3,4, Ethan McLeod1,
Matthew Raymond1,5, Oleg Moskvin 1, Catherine E. Zimmerman1, Derek J. Theisen 1, Scott Swanson 6,
Owen J. Tamplin 7, Leonard I. Zon 8, James A. Thomson6,9,10, Irwin D. Bernstein3,4 & Igor I. Slukvin 1,2,9
NOTCH signaling is required for the arterial speciﬁcation and formation of hematopoietic
stem cells (HSCs) and lympho-myeloid progenitors in the embryonic aorta-gonad-
mesonephros region and extraembryonic vasculature from a distinct lineage of vascular
endothelial cells with hemogenic potential. However, the role of NOTCH signaling in
hemogenic endothelium (HE) speciﬁcation from human pluripotent stem cell (hPSC) has not
been studied. Here, using a chemically deﬁned hPSC differentiation system combined with
the use of DLL1-Fc and DAPT to manipulate NOTCH, we discover that NOTCH activation in
hPSC-derived immature HE progenitors leads to formation of CD144+CD43−CD73−DLL4
+Runx1+ 23-GFP+ arterial-type HE, which requires NOTCH signaling to undergo endothelial-
to-hematopoietic transition and produce deﬁnitive lympho-myeloid and erythroid cells. These
ﬁndings demonstrate that NOTCH-mediated arterialization of HE is an essential prerequisite
for establishing deﬁnitive lympho-myeloid program and suggest that exploring molecular
pathways that lead to arterial speciﬁcation may aid in vitro approaches to enhance deﬁnitive
hematopoiesis from hPSCs.
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Generating autologous hematopoietic stem cells (HSCs)from induced pluripotent stem cells (iPSCs) that can beprecisely genetically modiﬁed with designer endonu-
cleases, and subsequently clonally selected, represents a promising
approach for patient-speciﬁc gene therapies. Although multiple
studies were able to generate hematopoietic progenitors (HPs)
with a HSC phenotype and limited engraftment potential from
pluripotent stem cells (PSCs)1–3, the robust and consistent
engraftment with recapitulation of the full spectrum of terminally
differentiated hematopoietic cells, including lymphoid cells, has
not been achieved. Thus, identifying key cellular and molecular
programs required for proper HSC speciﬁcation in vitro is
essential to overcome the current roadblocks.
During in vivo development, HSCs emerge by budding from
hemogenic endothelium (HE) lining arterial vessels, primarily
from the ventral wall of the dorsal aorta4,5. NOTCH signaling is
essential for arterial speciﬁcation and generation of HSCs6,7.
Notch1−/−, Dll4−/− and Rbpjk−/− mice, which are embryonic
lethal, have severe impairment in arterial vasculogenesis, fail to
develop the dorsal artery6,8,9, and lack intra-embryonic hemato-
poiesis. NOTCH signaling is also required for the acquisition of
arterial identity in extraembryonic vessels, including the yolk sac
vasculature10,11 and the speciﬁcation of Flk-1+c-Kit+CD31
+CD45− hemogenic progenitors within yolk sac12. Notably,
deﬁnitive HPs with lymphoid potential in the yolk sac, umbilical
cord and vitelline vessels only emerge within the arterial
vasculature13,14. In contrast, the primitive extraembryonic wave
of erythropoiesis and the ﬁrst wave of deﬁnitive yolk sac erythro-
myelopoiesis (EMP), which lack lymphoid potential, are not
NOTCH-depend or speciﬁc to the arterial vessels6,9,13,15. The lack
of venous contribution to HSCs along with the shared require-
ments of Notch, VEGF, and Hedgehog signaling for both arterial
fate acquisition and HSC development16–19 led to the hypothesis
that arterial speciﬁcation could be a critical prerequisite for HSC
formation. However, a direct progenitor-progeny link between
arterial speciﬁcation and deﬁnitive hematopoiesis has never been
demonstrated. Moreover, demonstration in recent studies show-
ing that HE represents a distinct CD73− lineage of endothelial
cells20,21 and that hematopoietic speciﬁcation is initiated at the
HE stage22–24 raises the question whether NOTCH signaling at
arterial sites creates a permissive environment for HSC devel-
opment following endothelial-to-hematopoietic transition (EHT),
or that arterial speciﬁcation per se is required for HE to become
HSCs. Although, recent studies have demonstrated that NOTCH
activation induces arterialization of CD73+ non-HE21, and that
NOTCH inhibition with DAPT reduces production of CD45+
cells from CD34+CD43−CD73− HE progenitors21,25, the effect of
NOTCH signaling on HE speciﬁcation has never been explored.
Here, using a chemically deﬁned human pluripotent stem cell
(hPSC) differentiation system combined with the use of DLL1-Fc
and the small molecule DAPT to manipulate NOTCH signaling
following the emergence of the well-deﬁned CD144+CD43
−CD73− population of HE during EHT, we discover that
NOTCH activation leads to the formation of arterial-type CD144
+CD43−CD73−DLL4+ HE (AHE) that expresses arterial markers
and possesses deﬁnitive lympho-myeloid and erythroid poten-
tials. Using a transgenic reporter WA01, human embryonic stem
cells (hESCs) in which the Runx1+ 23 enhancer mediates eGFP
expression, we ﬁnd that only DLL4+, and not DLL4−, HE cells,
demonstrate enhancer activity that is typically found in HE at
sites of deﬁnitive hematopoiesis in mouse and zebra ﬁsh
embryos26–28. Hematopoiesis from CD144+CD43−CD73−DLL4
+ AHE requires stroma and is strictly dependent on NOTCH
activation. In contrast, NOTCH modulation has limited effect on
EHT from the HE fraction that remains DLL4− following
NOTCH activation, indicating that deﬁnitive hematopoietic
activity segregates to AHE. Together, these studies establish a
direct progenitor-progeny link between arterialization of HE and
embryonic deﬁnitive hematopoiesis and reveal that NOTCH-
mediated induction of AHE is an important prerequisite for
establishing the deﬁnitive hematopoietic program from hPSCs.
Results
DLL1-Fc increases hematopoiesis and NOTCH signaling in
HE. In order to determine the direct effect of NOTCH signaling
on hematoendothelial differentiation from hPSCs, we utilized a
modiﬁed version of the serum- and feeder-free differentiation
system described previously29, where we identiﬁed developmental
stage equivalencies to in vivo development that can be identiﬁed
by cell-surface antigens and functional assays on speciﬁc days of
differentiation; Day 2–3 APLNR+PDGFRα+ Primitive Mesoderm
(D2 or D3 PM), Day 4 KDRhiPDGFRαlow/−CD31− Hematovas-
cular Mesoderm Precursors (D4 HVMP), Day 4 and 5 CD144
+CD43−CD73− Hemogenic Endothelial Cells (D4 or D5 HE),
and Day 8 CD34+CD43+ HPs (D8 HP)20,29. During differ-
entiation, we found that the NOTCH1 receptor is ﬁrst highly
expressed on D4 HE cells while the NOTCH ligand, DLL4, is ﬁrst
expressed on D5 within the CD144+ (VE-Cadherin) population
(Fig. 1a), suggesting that NOTCH signaling in hPSC cultures is
established at the time of HE formation.
Following the establishment of optimal conditions for EHT
culture in deﬁned feeder- and serum-free conditions, we isolated
D4 HE by magnetic enrichment of CD31+ cells, since at this stage
(Fig. 1a), the CD31+ population is entirely CD144+CD43−CD73
−DLL4− 20,29 (Supplementary Fig. 1a). Isolated D4 HE cells were
cultured either in control conditions, with the small molecule
gamma-secretase inhibitor, DAPT, to inhibit NOTCH signaling,
or were plated onto the immobilized NOTCH ligand DLL1-Fc to
activate NOTCH signaling30,31 (Fig. 1b). As we conﬁrmed by
western blot analysis of the active form of NOTCH1, NOTCH:
ICD, and qPCR analysis of the downstream NOTCH1 target
gene, HES1, by qPCR, these respective conditions efﬁciently
inhibited and activated NOTCH signaling (Fig. 1c, d). Kinetic
analysis of CD144 (endothelial marker) and CD43 (hematopoie-
tic marker) from D4+ 1 to D4+ 4 reveals a signiﬁcant increase
in hematopoiesis in the NOTCH activation condition and a
signiﬁcant decrease in hematopoiesis in the NOTCH inhibition
condition, compared to control (Fig. 1e). These results were
consistent with other hESC and hiPSC lines (Supplementary
Fig. 1b). In addition, similar results were obtained when D4 HE
cells are cultured in serum-containing medium on wild-type
OP9 stromal cells or OP9 cells transduced with human DLL4
(OP9-DLL4; Supplementary Fig. 1c). We also observe a
signiﬁcant increase in the total hematopoietic cell number in
the NOTCH activation condition (Fig. 1f, two-way ANOVA,
Bonferroni post-hoc test). The effect of DLL1-Fc on hematopoi-
esis increased as the concentration of immobilized DLL1-Fc and
cell density increased (Supplementary Fig. 1e). In contrast, culture
of D4 HE on immobilized JAG1-Fc or OP9-JAG1 minimally
affected hematopoiesis as compared to controls (Supplementary
Fig. 1d, f), thereby suggesting suboptimal activation of NOTCH
signaling by JAG1.
NOTCH activation facilitates EHT in HE. The increase in
hematopoiesis due to increased NOTCH signaling can be
attributed to three reasons: (1) increased EHT, (2) increased
hematopoietic expansion, or (3) increased survival post-EHT. To
evaluate these possibilities, we isolated D4 HE cells and cultured
them with DAPT for either 1 day during initiation of EHT (from
D4 to D4+ 1), or throughout the entire culture (D4 to D4+ 4),
followed by kinetic analysis of CD43 and CD144 expression on
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Fig. 1 NOTCH activation increases hematopoiesis from D4 HE. a NOTCH1 receptor expression is ﬁrst detected on D4 CD144+ cells. DLL4 expression is
ﬁrst detected on D5 CD144+ endothelial cells. b Schematic diagram of experiments. Cells were differentiated for 4 days on collagen IV, D4 CD144+CD43
−CD73− HE cells were puriﬁed using CD31 microbeads and plated in 3 different NOTCH conditions. cWestern blot of D4 HE cultured for 24 h (D4+ 1) in
presence of DAPT or DLL1-Fc shows a decrease in the activated cleaved form of NOTCH1 in DAPT-treated cells, and an increase in the activated cleaved
form of NOTCH1 in cells plated on DLL1-Fc. d qPCR analysis shows decreased HES1 mRNA expression in D4 HE cultured for 12 h (D4+ 0.5) with DAPT,
while HES1 mRNA expression is increased in cells plated on DLL1-Fc. Results are mean ± s.e.m. for three independent experiments; two-way ANOVA
Bonferroni post-hoc test, ***p < 0.01. e Flow cytometry on each day from D4+ 1 to D4+ 4 shows decreased CD43+ HPs in the cultures treated with
DAPT, and increased HPs in the cultures plated on DLL1-Fc. Representative contour plots from three independent experiments are shown. f Total numbers
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each day of the culture period (Fig. 2a). Following culture in
deﬁned conditions, HE weakly upregulate CD43 expression on
D4+ 1, but retain ﬂat endothelial morphology. Round CD43hi
cells that have completed EHT appear after D4+ 232. As shown
in Fig. 2b, c, HE treated for 24-hours with DAPT from D4 to D4
+ 1 weakly express CD43 along with CD144 on D4+ 1, but fail
to complete EHT efﬁciently, as evidenced by a signiﬁcant drop in
CD43hiCD144− cells on D4+ 2 through D4+ 4, although DAPT
treatment throughout (D4 to D4+ 4) more profoundly decreased
hematopoiesis (two-way ANOVA, Bonferroni post-hoc test).
To further verify that NOTCH activation affects EHT, we also
performed a single-cell deposition assay of the D4 HE using the
OP9 stromal cells and serum-containing medium that support
hematoendothelial development from single cells. Using a DOX-
inducible DLL4 OP9 cell line (OP9-iDLL4), we deposited D4 HE
onto 96-well plates of three different conditions; OP9-iDLL4 with
DAPT without DOX-pretreatment (NOTCH inhibition condi-
tion), OP9-iDLL4 with DMSO without DOX-pretreatment
(control condition), and OP9-iDLL4 with DMSO with pretreat-
ment of DOX (NOTCH activation condition). We found that D4
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HE in the NOTCH inhibition condition had a markedly
decreased ratio of hematopoietic/endothelial colonies compared
to D4 HE cells in the control condition. In contrast, the D4 HE in
the NOTCH activation condition had substantially increased
ratio of hematopoietic colonies compared to D4 HE in the
NOTCH inhibition condition, and a slight increase compared to
D4 HE in the control condition (Fig. 2d). Due to the well-
recognized fragility of hPSC-derived HE and survival after single-
cell sorting1,21, we found that less than 20% of single cells form
endothelial or hematopoietic colonies. Nevertheless, the total
number of colonies was consistent across each of the three
NOTCH conditions, indicating that the sorting experiments were
not affected by differences in cell viability.
We also stained the puriﬁed D4 HE before plating with
CellTracer to track cell proliferation. When we analyzed the cells
in each of the three NOTCH conditions on D4+ 1, we found that
there was a statistically signiﬁcant increase in the proportion of
CD144+CD43+ to CD144+CD43− cells within the ﬁrst genera-
tion of cells in the NOTCH activation condition (+DLL-Fc),
when compared to the NOTCH inhibition (+DAPT) condition
(two-way ANOVA, Bonferroni post-hoc test). This result, in
combination with the absence of a second generation on D4+ 1,
suggests that the activation of NOTCH signaling at HE stage
potentiate EHT initiation, but not proliferation (Fig. 2e, f).
Assessment of cell proliferation on D4+ 4 with CellTracer in
cultures treated with DAPT through D4+ 4 revealed no
signiﬁcant shift in distribution of CD43+ cells within each
generation (Fig. 2g and Supplementary Fig. 2a), consistent with
the lack of NOTCH effect of post-EHT expansion. In addition,
analysis of cell cycle in these cultures using EdU, demonstrated
no differences in cycling CD43+ cells in the different NOTCH
conditions (Supplementary Fig. 2b, c).
To evaluate whether NOTCH signaling affects apoptosis, we
performed Annexin V ﬂow cytometric analysis of HE cultured
with DAPT, DMSO, or on DLL1-Fc on D4+ 4. As shown in
Supplementary Fig. 3a, b, none of the conditions affected
apoptosis of blood cells post-transition, suggesting that the
difference in hematopoiesis from HE following manipulation of
NOTCH signaling is not attributed to the NOTCH effect on cell
survival.
Together, these results suggest that NOTCH activation at the
HE stage facilitates EHT, but has minimal effect on expansion or
survival of blood cells at the post-EHT stage.
NOTCH activation increases deﬁnitive hematopoiesis from
HE. Next, we determine whether NOTCH has an effect on HPs
emerging through EHT. Although NOTCH1 expression decreases
among the CD144+ endothelial population from D4+ 1 to D4+
4, CD144−CD43+ blood cells increase and maintain expression
of NOTCH1 post-transition from D4+ 2 to D4+ 4, notably
among the CD34+ subpopulation (Supplementary Fig. 4a,b),
thereby indicating that emerging blood cells are equipped to
respond to NOTCH signaling. To determine how NOTCH affects
post-EHT hematopoietic differentiation, we collected cells from
D4+ 4 HE cultures from the 3 different NOTCH conditions
(DAPT, DMSO, or DLL1-Fc) and plated them in methylcellulose
to measure their colony forming potential. The total number of
colonies was signiﬁcantly lower in the DAPT-treated NOTCH
inhibition condition, while there was no signiﬁcant change in the
total number of colonies between the control condition and the
NOTCH activation condition. Critically, however, there was a
statistically signiﬁcant increase in multipotent GEMM-CFCs and
GM-CFCs, as well as in E-CFCs among the HP cells from the HE
cultured in NOTCH activation condition compared to control
(Fig. 3a, two-way ANOVA, Bonferroni post-hoc test). These
results suggest that NOTCH activation maintains multilineage
potential of emerging HPs.
Next, we determined whether increased NOTCH activation
increases deﬁnitive-type hematopoiesis. Previously, the Runx1+
23 enhancer was found to be active in all HPs, including yolk sac.
HE found in regions where deﬁnitive hematopoiesis emerges have
also been found to activate Runx1+ 23, including the para-aortic
splanchnopleura, AGM region, vitelline, and umbilical arteries26–
28,33,34. We generated a hESC reporter line with Runx1+ 23
enhancer driving eGFP expression knocked into the AAVS1 locus
(Supplementary Fig. 5a, b). We differentiated the Runx1+ 23 cell
line, puriﬁed the D4 HE cells, and plated them in each of the 3
NOTCH conditions. Critically, there was signiﬁcantly higher
eGFP expression from D4+ 1 to D4+ 4 that emerge from the
CD144+ population in the NOTCH activation condition
compared to the control. In contrast, cells treated with DAPT
(NOTCH inhibition) had less eGFP expression compared to the
control (Fig. 3b).
T-cell potential is another hallmark of deﬁnitive hematopoi-
esis35. Comparative analysis of T-cell potential of the D4+ 4
CD43+ cells from DAPT, DLL1-Fc, and control conditions
revealed that HPs from the NOTCH inhibition condition had no
T-cell potential, while HPs from the NOTCH activation
condition had signiﬁcantly increased T-cell potential compared
to HPs from the control condition (Fig. 3c, one-way ANOVA
Bonferroni post-hoc test). In a separate assay, we collected
ﬂoating HPs on D4+ 4 and continued culture in a modiﬁed
erythrocyte expansion condition36. After 10 days, we collected the
cells and isolated mRNA to analyze their globin expression. We
found that erythrocytes generated from HPs from the NOTCH
activation condition have signiﬁcantly increased ratios of adult-
type β-globin expression to embryonic ε-globin and fetal γ-globin
expression, and the ratio of adult-type α-globin expression to
embryonic ζ-globin expression, when compared to the erythro-
cytes generated from HPs from both the NOTCH inhibition
condition and the control condition (Fig. 3d, one-way ANOVA
Fig. 2 Increased NOTCH activation facilitates EHT. a Schematic diagram of experiments. D4 HE cultured in presence of DAPT for 4 days (D4+ 4) or 1 day
(D4+ 1), or DMSO (control). CD144+ endothelial and CD43+ blood cells were analyzed following 4 days of culture. b Flow cytometric analysis
demonstrates that NOTCH activation facilitates EHT as evidenced by the decrease in hematopoietic activity when DAPT is added only from D4 to D4+ 1.
Representative contour plots from three independent experiments are shown. c Frequencies of endothelial and blood cells in HE cultures treated with
DAPT or DMSO (control). Results are mean ± s.e.m. for at least three independent experiments; two-way ANOVA Bonferroni post-hoc test, *p < 0.05, ***p
< 0.001. d Single D4 HE cells were FACS-sorted into 96-well plate with OP9, OP9+DAPT, and OP9-DLL4. Colonies were scored based on CD43 and
CD144 expression on D4+ 10 by immunoﬂuorescence and counted by eye. Scale bar represents 100 μm. e Representative ﬂow cytometric cell
proliferation analysis and f bar graph conducted with CellTracer shows an increase in the ﬁrst generation (Gen1) CD43+ cells on D4+ 1 and a proportional
decrease in Gen1 CD144+ endothelial cells, suggesting that the increase in blood cells is due to an increase in EHT and not just proliferating HPs. g Line
graph depicting the percent of each generation within the CD43+ population on D4+ 4 in each of the NOTCH treatment conditions. Results are mean ± s.
e.m. for three independent experiments; two-way ANOVA Bonferroni post-hoc test, *p < 0.05, ***p < 0.001. No signiﬁcant change of each generation
between conditions suggesting that NOTCH does not affect proliferation of HPs. Generation gates in f, g were determined by concatenating D4 to D4+ 4
results and utilizing FlowJo’s proliferation assay
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Bonferroni post-hoc test). Overall, these ﬁndings suggest that
NOTCH signaling is required for deﬁnitive hematopoietic stem/
progenitor cell speciﬁcation.
NOTCH activation induces DLL4+ HE with arterial identity.
Previously, we identiﬁed CD73 expression to demark the loss of
hemogenic potential within the D5 CD144+ endothelial popula-
tion20. As we demonstrated above, D4 HE cells lacked the
expression of the arterial marker, DLL4. However, when we
analyze CD73 and DLL4 expression within the D4+ 1 and D4+
2 CD144+ populations in each of the three NOTCH conditions,
we found a signiﬁcant increase in a unique transient population
of CD73−DLL4+ endothelial cells in the NOTCH activation
condition, and a delayed upregulation of CD73 expression on
DLL4+ endothelial cells compared to the NOTCH inhibition and
control conditions (Fig. 4a, b, two-way ANOVA Bonferroni post-
hoc test). In addition, when we analyze the CD144+ population of
the Runx1+ 23 cell line on D4+ 1, we found that all eGFP+ cells
are within the CD144+CD73−DLL4+ population (Fig. 4c and
Supplementary Fig. 5c). Since DLL4 is expressed by HE under-
lying intra-aortic hematopoietic clusters in the AGM37, our
results suggest that the DLL4+ population may resemble arterial-
type deﬁnitive HE found in arterial vasculature. To corroborate
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Fig. 3 NOTCH activation at HE stage increases deﬁnitive hematopoiesis. a D4 HE were cultured with DAPT or in the presence of DLL1-Fc (see Fig. 1b
schematic diagram). Cells were collected after 4 days of differentiation (D4+ 4) and used to determine frequencies of hematopoietic progenitors in CFU
assay. Increase in multipotential GEMM and GM colonies in the DLL1-Fc culture condition suggests that NOTCH activation supports expansion of the most
immature HPs. Results are mean ± s.e.m. for three independent experiments; two-way ANOVA Bonferroni post-hoc test, ***p < 0.001 b Flow cytometric
analysis of Runx1+ 23-eGFP transgene expression in D4 HEPs cultured with DAPT or on DLL1-Fc. Runx1+ 23 enhancer activity increases in the cultures
plated on DLL1-Fc and decreases in the DAPT-treated cultures. Representative contour plots from three independent experiments are shown. c T-cell
potential of HP collected after 4 days of culture D4 HEs in presence of DAPT or DLL1-Fc. Bars show mean ± s.e.m. for three independent experiments; one-
way ANOVA Bonferroni post-hoc test, **p < 0.01, ***p < 0.001. d Ratio of α/ζ, β/γ, and β/ε globin chain expression in erythroid cultures generated from D4
HE in presence of DAPT or DLL1-Fc. Results are mean ± s.e.m. for three independent experiments; one-way ANOVA Bonferroni post-hoc test, ***p < 0.001
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this hypothesis, we evaluated the expression of arterial, venous,
and deﬁnitive hematopoietic markers by real-time qPCR analysis
of sorted D4 CD144+CD43−CD73−HE that are DLL4− by
default (D4 HE) and D5 CD144+ endothelial subpopulations
CD144+CD43−CD73−DLL4+ (D5 HE:DLL4+), CD144+CD43
−CD73−DLL4− (D5 HE:DLL4−), and CD144+CD43−CD73
+DLL4− (D5 nonHE:DLL4−), (Fig. 4d). This analysis reveals that
the D5 HE:DLL4+ and nonHE:DLL4+ populations have
increased expression of NOTCH1, DLL4, EFNB2, HEY2, SOX17,
and CXCR4 genes associated with arterial endothelium, and
decreased expression of NR2F2 associated with venous endothe-
lium, when compared to D5 DLL4−HE and nonHE populations.
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In contrast, D5 HE:DLL4− demonstrated an increased expression
of NR2F2 venous marker. Importantly, genes associated with
deﬁnitive hematopoiesis, MYB and GATA2, were expressed sig-
niﬁcantly higher in the D5 HE:DLL4+ population compared to
the D5 HE:DLL4− population and D5 nonHE:DLL4+ popula-
tions (Fig. 4e, one-way ANOVA Bonferroni post-hoc test). We
also revealed that emerging D4 HE cells that are lacking DLL4
expression were different from D5 HE:DLL4− and D5 HE:DLL4+
cells. D4 HE did not express signiﬁcant levels of arterial and
venous markers, but retained expression of HAND1, which is
expressed in extraembryonic and lateral plate mesoderm38, sug-
gesting that D4 HE may represent immature HE cells.
Deﬁnitive HPs emerge from arterial-type HE. To determine the
hematopoietic potential of endothelium with arterial identity, we
continued differentiation of hPSCs to D5, and then sorted the D5
CD144+CD43−CD73−DLL4− (HE:DLL4−) and D5 CD144
+CD43−CD73−DLL4+ (HE:DLL4+) endothelial subpopulations
(Fig. 5a). Although we did not detect any CD43+ blood cells from
D5 HE:DLL4+ on D5+ 4 in serum- and feeder-free conditions
with or without DLL1-Fc, these cells did produce blood when
plated on OP9-DLL4 (Fig. 5b). In contrast, D5 HE:DLL4− cells
undergo EHT and develop HPs on D5+ 4 on both OP9 and
OP9-DLL4. However, unlike previously, when we used D4 HE
cells before they bifurcate into D5 HE:DLL4+ and D5 HE:DLL4−,
there was no signiﬁcant difference in blood production between
the D5 HE:DLL4− cells plated on OP9 vs. OP9-DLL4 (Fig. 5b, c,
two-way ANOVA Bonferroni post-hoc test). The results were
consistent across different iPSC lines as well (Supplementary
Fig. 6). In addition, DAPT treatment from D5 to D5+ 2, D5+ 2
to D5+ 4, and from D5 to D5+ 4 signiﬁcantly inhibited hema-
topoietic activity of the HE:DLL4+ population, while DAPT
treatment of HE:DLL4− cultures had no effect on hematopoietic
activity (Fig. 5d, two-way ANOVA Bonferroni post-hoc test),
suggesting that hematopoiesis from D5 HE:DLL4+, in contrast to
D5 HE:DLL4−, is NOTCH dependent.
Next, we determined whether the HPs from each of the D5 HE
subsets have differential deﬁnitive hematopoietic potential. When
the HPs from the D5 HE subpopulations were plated in colony
forming medium, the HPs that emerged from the HE:DLL4+
subpopulation cultured on OP9-DLL4 had increased colony
forming cells, particularly of GEMM-CFCs compared to the HPs
from D5 HE:DLL4− on OP9 and OP9-DLL4 (Fig. 5e, two-way
ANOVA Bonferroni post-hoc test).
When we collected the ﬂoating HPs derived from D5 HE:DLL4
− on OP9 and OP9-DLL4, and HPs derived from D5 HE:DLL4+
on OP9-DLL4, and continued to grow them in the aforemen-
tioned erythrocyte expansion and maturation culture36, we found
that erythrocytes generated from HPs derived from the D5 HE:
DLL4+ on OP9-DLL4 have signiﬁcantly increased ratios of β-
globin expression to ε-globin and γ-globin expression, and an
increased ratio of α-globin expression to ζ-globin expression,
when compared to the erythrocytes generated from HPs derived
from D5 HE:DLL4− on OP9 and OP9-DLL4 (Fig. 5f, one-way
ANOVA Bonferroni post-hoc test).
We also conducted a limiting dilution assay (LDA) for
lymphoid potential, and found that 1 in 14 HPs derived from
D5 HE:DLL4+ on OP9-DLL4 have T-cell potential, while 1 in 44
HPs derived from D5 HE:DLL4− on OP9-DLL4 have lymphoid
potential. Crucially, HPs derived from D5 HE:DLL4− on OP9
and D5 HE:DLL4− on OP9 with DAPT had only 1 in 10,706 and
1 in 10,895 had T-cell potential, respectively (Fig. 5g), thereby
suggesting that D5 HE:DLL4+ phenotype enriches for HE that
can produce HPs with T lymphoid potential.
In order to determine whether there are any molecular
differences between HPs derived from HE:DLL4+ and HE:
DLL4− cells, we performed RNA-seq analysis of CD235a/CD41a
−CD34+CD43+CD45+ cells generated from these two different
hemogenic endothelial cells following tertiary culture on either
OP9 or OP9-DLL4 (Fig. 6a). As a basis for the analysis, genes that
were differentially expressed in a three-way Bayesian model
involving HPs from HE:DLL4− on OP9 (condition 1), HE:DLL4−
on OP9-DLL4 (condition 2), and HE:DLL4+ on OP9-DLL4
(condition 3) were used with focus speciﬁcally on genes
upregulated in HE:DLL4+ vs. HE:DLL4−-derived HPs obtained
from OP9-DLL4 cocultures. Among 131 differentially expressed
genes in this category (Supplementary Dataset 1), we identiﬁed
two cell-surface markers of HSCs in AGM, ACE, and TEK, and
the following nine transcription factors: MECOM, GFI1B, and
ERG, essential for AGM and fetal liver hematopoiesis; ARID5B,
BCOR, and KDM6B, control lymphoid development39–41; ZNF93,
highly expressed in T-cells42; and RUNX1T1 and HOXB8,
regulate expansion of blood progenitors43,44 (Fig. 6b). Using the
known transcription-target relationships obtained by combining
largely complementary data from HTRIdb45 and CellNet46, 163
regulatory interactions involving 110 transcription factors
upstream of the nine differentially expressed transcription
factor-encoding genes were pulled to construct a regulatory
network in HPs derived from HE:DLL4+ cells on OP9-DLL4
(Fig. 6c). The database-derived structure of the network has been
conﬁrmed by our RNA-Seq data: transcription factors that are
active according to our regulon analysis (red nodes) are
apparently responsible for the upregulation of mRNA level of
the target genes (large nodes). Three out of nine target genes
(MECOM, RUNX1T1, and GFI1B) have also an evidence of their
protein-level activity (reddish color on the graph) detected as
enrichment of their known targets among the differentially
expressed genes. Importantly, GATA2, SOX17, SOX18, MYB,
PBX1, PRDM14, DACH1, KLF4, HOXA5, HOXA7, and NOTCH1
were identiﬁed as upstream regulators of these genes, thereby
suggesting that the molecular program in HPs derived from the
arterial-type HE:DLL4+ is driven by transcriptional regulators
implicated in arterial development and deﬁnitive hematopoiesis.
To further verify the link between arterialization and deﬁnitive
hematopoiesis, we assessed whether lymphoid development was
affected by arterial gene SOX17, which is indispensable for
acquisition and maintenance of arterial identity in the embryo47.
For this purpose, we transfected hESC differentiation cultures
with SOX17 siRNA at initiation of HE formation to achieve up to
50% reduction of SOX17 mRNA expression 48 h after treatment
Fig. 4 NOTCH activation induces formation of arterial-type HE cells. a Flow cytometric analysis of DLL4 and CD73 expression following culture of D4 HE
for 1 or 2 days in the presence of DAPT or DLL1-Fc. NOTCH activation on D4 HE speciﬁcally increases the CD144+CD73−DLL4+ population. b Frequencies
of DLL4+ cells in hemogenic (CD73−) and non-hemogenic fractions of endothelium following 1 and 2 days of culture of D4 HE in the presence of DAPT or
DLL1-Fc. Results are mean ± s.e.m. for three independent experiments; two-way ANOVA Bonferroni post-hoc test, *p < 0.05, **p < 0.01, ***p < 0.001. c
Flow cytometric analysis of Runx1+ 23 enhancer activity following 1 day of culture of D4 HE in presence of DAPT or DLL1-Fc. Runx1+ 23 enhancer activity
is limited to the CD144+CD73−DLL4+ population. Representative contour plots from two independent experiments are shown. d Schematic diagram of
FACS isolation of endothelial subpopulations formed on D5 of differentiation. e qPCR analysis of arterial (NOTCH1, DLL4, EFNB2, HEY2, SOX17, CXCR4),
venous (NR2F2), hematopoietic (MYB, GATA2), and mesodermal (HAND1) genes in D4 HE and D5 endothelial subpopulations. Results are mean ± s.e.m.
for three independent experiments; one-way ANOVA Bonferroni post-hoc test, *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 5 Arterial-type HE undergoes EHT under high NOTCH activation and produce deﬁnitive-type HPs. a Schematic diagram of subsequent experiments.
D5 CD144+CD43−CD73− were sorted based on DLL4 expression (D5 HE:DLL4+/−) using FACS and cultured on either OP9 or OP9-DLL4 for 4 days (D5
+ 4). b, c Flow cytometric analysis of CD43+ hematopoietic and CD144+ endothelial cells following culture of D5 HE:DLL4+ and D5 HE:DLL4− on either
OP9 or OP9-DLL4. Bars in c are mean ± s.e.m. for at least three independent experiments. Two-way ANOVA Bonferroni post-hoc test, *p < 0.05. d The
effect of NOTCH inhibition with DAPT on blood production from D5 DLL4+ and DLL4− HE. No signiﬁcant differences were found when HE:DLL4− cells
were treated with DAPT. Results are mean ± s.e.m. for three independent experiments. Two-way ANOVA Bonferroni post-hoc test, ***p < 0.001. e CFC
potential of hematopoietic cells generated from D5 DLL4+ and DLL4− HE following 5 days culture on OP9-DLL4. Results are mean ± s.e.m. for at least
three independent experiments; two-way ANOVA Bonferroni post-hoc test, *p < 0.05, **p < 0.01. CFC-GEMMs are signiﬁcantly increased in DLL4+
cultures on OP9-DLL4. f Ratio of α/ζ, β/γ, and β/ε globin chain expression in erythroid cultures generated form hematopoietic cells collected from D5
DLL4+ and DLL4− HE cultured on OP9-DLL4 (D5+ 4 cells). Results are mean ± s.e.m. for three independent experiments. one-way ANOVA Bonferroni
post-hoc test, **p < 0.01, ***p < 0.001. g Limiting dilution assay to determine the frequency of T-cell progenitors within the D5+ 5 HPs generated from HE:
DLL4− on OP9, HE:DLL4− on OP9-DLL4, and HE:DLL4+ on OP9-DLL4
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Fig. 6 HPs derived from DLL4+ HE cells activate deﬁnitive hematopoietic program. a Experimental strategy for generating and characterizing HE:DLL4+/−
-derived HPs. D4 HE cells where cultured on DLL1-Fc for 24 h, followed by puriﬁcation of D4+ 1 HE:DLL4+ and HE:DLL4− and subsequent culture on OP9
or OP9-DLL4. Five days later (D4+ 1+ 5), CD34+CD43+CD45+CD235a/41a− population was FACSorted from each condition and RNA was extracted
for RNA-seq. b A heatmap of differentially expressed transcription factor genes in HPs derived from indicated cell populations. The expression is shown as
a log ratio of gene expression relative to HPs generated from HE:DLL4− cells on OP9-DLL4. c Transcriptional regulatory network reconstructed with the
nine transcription factor-encoding genes (the nodes with incoming interactions) differentially expressed in HPs derived from HE:DLL4+. Size of the nodes
represents relative abundance of mRNA of the respective gene, computed as log2(fold change) in DLL4+ vs. DLL4−(see circle size scale below).
Statistically insigniﬁcant changes in mRNA abundance (examples: GATA1, GATA2) were set to zero. Upregulation effects are mapped onto the node size
as indicated. The color density represents enrichment of known targets of that transcription factor (regulon members) among the differentially expressed
genes (see −log10(FDR) color scale below). Network visualization was performed using Cytoscape ver. 3.4.074. d Schematic diagram of NOTCH
regulation on HE speciﬁcation and EHT. The most immature hPSC-derived CD144+CD43−CD73− HE cells expressing NOTCH1 but lacking arterial and
venous identity arise on day 4 of differentiation. NOTCH activation induces speciﬁcation of immature HE into DLL4+ arterial-type HE, ﬁrst detectable on
day 5 of differentiation. Hematopoiesis from arterial-type HE:DLL4+ is NOTCH dependent and produces deﬁnitive hematopoietic progenitors. Day 4 HE
cells that are not DLL4+ by day 5 of differentiation undergo EHT independent of NOTCH activation and produce NOTCH-independent hematopoietic
progenitors with primitive potential
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(Supplementary Fig. 7a). As shown in Supplementary Fig. 7b, c,
siRNA-mediated SOX17 knockdown markedly reduced percen-
tages and absolute numbers of T-cells produced from hESC-
derived HPs, thereby providing direct evidence that arterial gene
SOX17 is required for establishing deﬁnitive hematopoiesis.
RNAseq analysis of NOTCH ligands, receptors, and their
downstream targets in D5 DLL4+ and DLL4− HE, and HPs
obtained from these populations, revealed D5 DLL4+ AHE
express greater levels of NOTCH1, NOTCH4, DLL4, and JAG2 as
compared to DLL4− HE. However, expression of NOTCH-
associated molecules and SOX17 was substantially lower in HPs,
including HPs generated from DLL4+ AHE on OP9-DLL4,
suggesting a downregulation of NOTCH signaling and arterial
program following EHT (Supplementary Fig. 8). These ﬁndings
are consistent with observations in the mouse system which
demonstrated that downregulation of NOTCH1 and SOX17 is
essential for EHT48. The exact mechanism of NOTCH down-
regulation at EHT stage remains unknown. Although NOTCH
receptors are activated by cell-surface ligands in neighboring cells
(trans-activation of NOTCH), NOTCH ligands expressed by the
same cell typically inactivate NOTCH signaling (cis-inhibition of
NOTCH)49. Although the response to trans-Delta is graded, cis-
Delta response is abrupt and occurs at ﬁxed threshold50. Thus, it
is likely that in response to trans-DLL4 signaling from OP9-
DLL4, AHE upregulates DLL4 expression to the threshold level
required for cis-inhibition of NOTCH signaling in its own
NOTCH1-expressing AHE cells, thereby allowing for EHT to
proceed. This interpretation is consistent with studies in the
mouse system, which have demonstrated that expression of
NOTCH ligands, including DLL1 and DLL4, in the AGM
vascular niche with co-expression of DLL4 and NOTCH1 on
emerging hematopoietic cells is critical for HE to undergo EHT
and subsequent HSC ampliﬁcation through limiting NOTCH1
receptor activation by cis-inhibition30,51. However, despite down-
regulation of SOX17 and NOTCH1 expression following
transition from DLL4+ HE, we observed an enrichment of their
known target genes (regulon members) in lin−CD34+CD45+
progenitors at post-EHT stage in OP9-DLL4 cultures (Fig. 6c).
These ﬁnding suggest that following EHT, the expression of
arterial genes decreases, but downstream program activated by
these genes in the presence of NOTCH ligands remains active.
Together, these results imply that arterial-type CD144+
CD43−CD73−DLL4+ HE represents the precursor of deﬁnitive
NOTCH-dependent hematopoiesis with broad lympho-myeloid
and deﬁnitive erythroid potential, while the CD144+CD43−
CD73−DLL4− phenotype is associated with emerging immature
HE endothelium (D4) or HE that has primitive NOTCH-
independent hematopoietic potential (D5).
Discussion
In the current study, we revealed that NOTCH signaling is
essential for speciﬁcation of deﬁnitive lympho-myeloid hemato-
poiesis by eliciting arterial speciﬁcation of HE from hPSCs. We
demonstrated that NOTCH activation promotes formation of
transient CD144+CD43−CD73−DLL4+ HE population with high
expression of arterial genes and active Runx1+ 23 enhancer that
mark arterial-type HE in AGM, umbilical, and vitelline
arteries26,27,33,34,37. Although CD144+CD43−CD73−DLL4+
AHE have lower hemogenic capacity compared to DLL4− HE,
the hematopoietic potential of AHE is strictly NOTCH depen-
dent. AHE is speciﬁed from CD144+CD43−CD73−DLL4−
immature HE cells emerging on D4 of differentiation in a
NOTCH-dependent manner following acquisition of an
arterial CD144+CD43−CD73−DLL4+ phenotype, while CD144+
CD43−CD73−DLL4− HE cells that failed to undergo arterial
speciﬁcation on day 5 of differentiation retained mostly primitive
hematopoietic potential and were minimally affected by NOTCH
activation (Fig. 6d). Demonstrating that deﬁnitive hematopoietic
potential is highly enriched in arterial-type HE is in concordance
with in vivo studies that established the restriction of lymphoid
cell and HSC formation to the arterial vasculature in the yolk sac
and embryo proper5,13,14, enrichment of HSC precursors in
DLL4+ HE in AGM region51, and selective impairment of AGM
hematopoiesis in Efnb2−/− mice52. Notably, DLL4+ HE pro-
duced blood cells only on OP9-DLL4, but failed to undergo EHT
in DLL1-Fc cultures in deﬁned serum- and stroma-free condi-
tions, suggesting that AHE, in contrast to non-AHE, requires
some additional signaling factor, either soluble factors in serum,
matrix proteins or a paracrine signaling between the OP9-DLL4
and AHE, that are necessary for EHT, but have yet to be
determined.
Previous studies have found that NOTCH pathways are active
during hematopoietic differentiation of mouse and hPSCs. The
transient NOTCH activation increased the generation of CD45+
HPs25,53,54 and NOTCH inhibition with DAPT decreased
the percentage of CD45+ cells in cultures of hPSC-derived
CD34+CD73−CD43− progenitors21. NOTCH activation in hPSC
cultures is predominantly mediated through the NOTCH ligand,
DLL4, expressed by endothelial cells25. However, since prior
studies demonstrated that NOTCH signaling also contributes to
expansion of embryonic and fetal HSPCs30,31 and affects HSPC
survival55, it remains unclear whether DAPT treatment effects
observed in prior PSC studies could be attributed to the NOTCH
effect on EHT, post-EHT expansion or HP survival. It is also
unknown, whether NOTCH signaling affects HE speciﬁcation. In
the present study, we provided evidence that NOTCH has several
effects on hematopoiesis from HE. First, we demonstrated that
NOTCH signaling is important for the speciﬁcation of arterial-
type HE cells with deﬁnitive hematopoietic program. In addition,
NOTCH activation also potentiates the EHT from these cells,
while having little effect on expansion and survival of blood cells
at post-EHT stage.
Overall, our studies indicate that regulation of NOTCH signaling
would be important to mimic the arterial HE, deﬁnitive lympho-
myeloid hematopoiesis and HSC speciﬁcation in hPSC culture.
Nevertheless, we failed to achieve engraftment from NOTCH-
activated cultures in our pilot studies. As previous studies have
shown, the timing56 and strength57 of NOTCH signaling is tightly
regulated during EHT and post-EHT. In mouse embryo, NOTCH
signaling is especially critical for pre-HSC type I (VE-Cad+
CD45−CD41+CD43+) development and their transition into
pre-HSC type II (Ve-Cad+CD45+CD41+CD43+) in the AGM,
however later stages of HSC development are less dependent on
NOTCH58. Thus, NOTCH signaling may need to be ﬁne-tuned in
hPSC cultures to establish long-term engrafting HSCs. It is also
likely that acquisition of arterial features by HE is a necessary but
not a sufﬁcient prerequisite for HSC formation from hPSCs. In yolk
sac, arterial vessels in contrast to venous vessels and capillaries
produce lymphoid cells13, yet arterial speciﬁcation at extra-
embryonic sites is not associated with establishing HSC program.
Several signaling pathways, including those uncoupled from aortic
speciﬁcation such as HOXA1,59,60, TGFβ61, retinoic acid59,62,
inﬂammation63,64, hormone65,66, and blood-ﬂow-induced shear
stress67,68, have all been shown to serve roles during HSC devel-
opment and may be affected in in vitro generated cells. The
investigation of the cross-talk among all of these different signaling
pathways and manipulating them together is probably necessary to
recapitulate embryonic deﬁnitive hematopoietic development and
generate HSCs with robust and sustainable multilineage engraft-
ment potential de novo.
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Methods
hPSC maintenance and differentiation. hPSCs, H1 and H9 hESC lines, DF19-9-
7T ﬁbroblast-hiPSC line, IISH2i-BM9 bone marrow-iPSC line, and IISH3i-CB6
cord blood-iPSC line (all from WiCell) were maintained and passaged in chemi-
cally deﬁned conditions using vitronectin and E8 media and tested every 6 months
for mycoplasma contamination. The hPSCs were differentiated into hema-
toendothelial lineages using a chemically deﬁned conditions29. On Day −1, hPSCs
were singularized and plated on collagen IV-coated plates (0.5 μg/cm2) at a cell
density of 7500 cells/cm2 in E8 media supplemented with 10 uM Rock inhibitor (Y-
27632, Cayman Chemicals). On Day 0, the media was changed to IF9S media
supplemented with BMP4, FGF2 (50 ng ml−1), Activin A (15 ng ml−1, Peprotech),
LiCl (2 mM, Sigma), and ROCK inhibitor (0.5 μM, Cayman Chemicals) and cul-
tured in hypoxia (5% O2, 5% CO2). On day 2, the media was changed to IF9S
media supplemented with FGF2, VEGF (50 ng ml−1, Peprotech), and 2.5 μM TGFβ
inhibitor (SB-431542, Cayman Chemicals). On day 4, cell cultures were singular-
ized and stained with anti-CD31 microbeads (Miltenyi) for 15 min. The cells were
washed and HE were puriﬁed using CD31 antibody and MACS LS columns
(Miltenyi). Puriﬁed CD31+ HE were then plated at a density of 20,000 to 30,000
cells/cm2 on collagen IV-coated plates (1 μg/cm2) that were either co-coated with
IgG-Fc fragments or human DLL1-Fc (made in-house), in IF9S media supple-
mented with FGF2, VEGF, EGF, IGF-I, IGF-II, TPO, IL-6 (50 ng ml−1), SCF (20
ng ml−1), IL-3, FLT3L (10 ng ml−1, Peprotech), and ROCK inhibitor (5 μM,
Cayman Chemicals), and where speciﬁed, DMSO (1:1000, Fisher Scientiﬁc) or
DAPT (10 μM, Cayman Chemicals), and cultured in normoxia (20% O2, 5% CO2).
In some experiments, HE was cultured on plates co-coated with human JAG1-Fc
(R&D Systems). A sample of the puriﬁed cells was analyzed by ﬂow cytometry, and
experiments were continued only if the purity of the HE was over 95% CD144+.
On Day 4+ 1, the media was replaced with fresh media containing the same
supplements without ROCK inhibitor. On day 4+ 3, extra media with the same
supplements was added to the culture.
OP9 maintenance and co-culture. Mouse OP9 stromal cell line was kindly pro-
vided by Dr. Toru Nakano (Osaka University, Osaka, Japan). OP9, OP9-DLL4, and
the inducible OP9-iDLL4 (made in-house) cell lines were maintained in αMEM with
20% FBS (GE) on gelatin-coated plates in normoxia. Using TrypLE (Thermo), OP9
were passaged at a 1:8 ratio every 3–4 days when they were 80% conﬂuent. One day
before co-culture with differentiated human HE cells, OP9 lines were treated with
mitomycin C (1mgml−1) for 2 h and then plated at a density of 12,500 cells/cm2. D4
HE cells or D5 CD144+ subsets were plated onto OP9 lines at a density between 1000
and 2000 cells/cm2 in media containing αMEM with 10% FBS (GE), TPO, SCF, IL-6
(50 ng/ml), IL-3, and FLT3L (10 ng/ml). Media was changed after 24 h, and extra
media added 2 days later. Experiments conducted with DAPT were treated with 20
μM, while corresponding control conditions had DMSO added at a 1:500 dilution.
Generation of OP9-DLL4, OP9-JAG1, and DOX-inducible OP9-iDLL4. Human
DLL4 gene fragment was ampliﬁed by PCR from a vector previously used to
establish the OP9-DLL4 cell line, and the JAG1 gene was ampliﬁed by PCR from
cDNA of D5 differentiation cultures that were treated with Sonic Hedgehog from
D2–5, which has been found to increase Jag1 expression. The DLL4 and JAG1 gene
fragment was subsequently cloned into a pSIN-EF1a-DLL4−IRES-Puro and pSIN-
EF1a-JAG1-IRES-Puro lentiviral expression vector for the constitutively expressed
OP9- DLL4 and JAG1 lines, respectively. Virus production and concentration was
carried out by calcium phosphate transfection of Lenti-X 293T-cells (Clonetech,
Mountain View, CA). After 12 h, virus-containing medium was replaced with fresh
OP9 culture medium. After 3 days, the cells were treated with Puromycin for
2 weeks. For dox-inducible OP9-DLL4, the DLL4 gene fragment was subsequently
cloned into a pPB-TRE-DLL4−P2A-Venus-EF1α-Zeo||EF1a-M2rtTA-T2A-Puro
PiggyBac vector made in-house. OP9 cells were then transfected with pPB vector.
Three days later the transfected OP9 cells were treated with Puromycin/Zeocin for
2 weeks. Samples of the OP9-iDLL4 cells were treated with doxycycline for 24 h,
then DLL4 and Venus expression were conﬁrmed by ﬂow cytometry.
Single-cell deposition assay for EHT. One day before single-cell deposition, the
OP9-iDLL4 cell line was treated with mitomycin C as described above, and pas-
saged into 96-well plates at a density of 12,500 cells/cm2. OP9-iDLL4 used for the
NOTCH activation condition was incubated with doxycycline for 24 h after pas-
saging into 96-well plates. On the day of single-cell sorting, OP9-iDLL4 media was
changed to αMEM with 10% FBS (GE), TPO, SCF, IL-6 (50 ng ml−1), IL-3, FLT3L
(10 ng ml−1), and DMSO (1:500) for the control, and NOTCH activation condi-
tions, or DAPT (20 μM) for the NOTCH inhibition condition. Day 4 differentiated
hPSCs were singularized, stained for CD309-PE and CD144-APC (Miltenyi Bio-
tech), and was single-cell sorted into individual wells of the 96-well plates using a
FACS Aria II. To exclude possibility of doublets, we used a low density (less than 1
million cells/ml) cells suspension, sorting speed less than 1000 cellular events/
per second and stringent gating on single cells using both FSC-A vs. FSC-H and
SSC-A vs. SSC-H. One day after sorting, the media was changed to fresh media
without DMSO or DAPT, and extra media was added every 3 days. Seven days
later, the plates were ﬁxed and stained for immunoﬂuorescent staining with anti-
CD144 (rabbit, eBiosceince) and anti-CD43 (mouse, BD Biosciences) primary
antibodies and anti-rabbit AlexaFluor488 and anti-mouse
AlexaFluor594 secondary antibodies (Jackson Immunology) in order to score the
hematopoietic/endothelial colonies.
CellTracer proliferation assay and cell-cycle analysis. D4 CD31+ HE cells were
incubated in PBS with CellTracer (1 μg ml−1, Thermo) for 20 min at 37 °C. After
washing, the cells were plated on collagen IV-coated plates with either Fc-IgG or
DLL1-Fc and the modiﬁed Day 4 media, as described above, at a higher density of
30,000–40,000 cells/cm2 due to toxicity from the CellTracer. Aliquots of the pur-
iﬁed cells were analyzed by ﬂow cytometry to determine the purity of the MACS
cells and establish the Generation 0 peak for the proliferation assay. Secondary
cultures were collected every day after plating for ﬂow cytometry analysis, and
calibration beads were used to generate compatible CellTracer results. After D4+
4, FlowJo Analysis software was used to concatenate the data from each day. The
average number of cell divisions was calculated based on the number of cells on
each day (Fig. 1f) and applied to the proliferation platform algorithm in Flowjo to
determine the speciﬁc generation gates. Those peaks were re-applied to individual
sets of data to determine the percentage of each generation within the hema-
toendothelial populations. Apoptosis was detected used annexin V ﬂow cytometry.
Fluorescent reagents used for analysis, cell viability, apoptosis, and proliferation are
listed in Supplementary Table 1. For cell-cycle analysis, D4+ 4 cells were incubated
in culture media with EdU (10 μM, Thermo Fisher) for 2 h and stained with CD43
and CD144 antibodies for 20 min. For EdU detection, the Click-IT EdU Alexa
Flour 647 kit (Thermo Fisher) with DAPI (4 μg ml−1, Sigma) was used.
T-Cell differentiation and T-cell LDA. Total D4+ 4 cultures were singularized,
strained, and cultured in T-cell differentiation conditions on OP9-DLL4 for
3 weeks29. For D5+ 4 cultures, only the ﬂoating hematopoietic cells were collected
and cultured in T-cell differentiation conditions. LDAs were conducted with the
ﬂoating cells collected from D5+ 4 cultures (HE:DLL4− on OP9+DAPT, OP9+
DMSO, and OP9-DLL4, and HE:DLL4+ on OP9-DLL4). Row A of a 96-well plate
received 500 cells/well, and each subsequent row afterwards had half the previous row
(Row B contained 250, Row C contained 125… Row H contained 3–4 cells). The
wells were scored 2 weeks later by eye and ﬂow-cytometry for CD5+CD7+ con-
taining cells. Positive threshold was set at 167 CD5+CD7+ cells/well. Extreme lim-
iting dilution analysis was conducted using the previously established algorithm69.
Red blood cell differentiation and maturation. In order to assess the deﬁnitive
erythropoietic potential of HP cells, we adopted our previously describe red blood cell
differentiation protocol36 to become chemically deﬁned and feeder- and serum-free.
Floating cells were collected, washed, and plated back into their respective cultures for
D4+ 5 cells, or plated onto collagen IV-coated plates for D5+ 4 cells, with IF9S
supplemented with dexamethasone (10 μM), EPO (2Uml−1), SCF, FLT3L, TPO, IL-
6 (100 ngml−1), and IL-3 (10 ngml−1). Extra media with the same supplements was
added 2 days later. An additional 2 days later, the cultures were treated with half-
media changes every 2 days with IF9S supplemented with dexamethasone (10 μM),
SCF (100 ngml−1), and EPO (2Uml−1). The ﬂoating cells were collected 10 days
later to analyze by ﬂow cytometry and RNA isolated for qPCR analysis.
Generating Runx1 + 23 enhancer reporter hESC line. Runx1+ 23 enhancer
fragment27 was ampliﬁed by PCR and subsequently cloned into the AAVS1-SA-2A-
PURO vector (gift from Gadue Lab, The Children’s Hospital of Philadelphia).
Human ESCs were transfected with zinc-ﬁnger nuclease vectors and later
puromycin-resistant individual cells were clonally expanded and on-targeted clones
were selected. Southern Blot (SB) analysis was performed by DIG-labeling hybridi-
zation (Roche). Brieﬂy, 10 μg genomic DNA was digested using a EcoRV restriction
enzyme for overnight, separated on a 0.7% agarose gel for 6 h, transferred to a nylon
membrane (Amersham), and incubated with DIG-labeling probes. The external
probe is a DIG-labeled 600 nucleotide fragment that binds to the EcoRV-digested
fragment of the 5′ external region. The internal probe is a DIG-labled 700 nucleotide
fragment that binds to the EcoRV-digested fragment of the of the eGFP region.
SOX17 knockdown in differentiation cultures using siRNA. hESCs were
transfected with 50 nM SOX17 siRNA SMARTpool (Dharmacon, GE) or 50 nM
scramble negative control siRNA (Dharmacon) on D3 of differentiation using
Lipofectamine 3000 (Invitrogen). To conﬁrm SOX17 knockdown, SOX17 mRNA
levels were assessed 48 h after transfection with qPCR. HPs from control and
SOX17 siRNA treated cultures were collected on day 8 of differentiation and
assessed for T-cell potential as described above.
Hematopoietic colony forming unit assay. Hematopoietic colony forming unit
assay was conducted in serum-containing H4436 Methocult (Stem Cell Technol-
ogies) according to manufacturer instruction.
Flow cytometry and FACS-sorting. Flow cytometry was conducted using the
MACSQuant Analyzer 10 (Miltenyi Biotech). FACS-sorting was conducted on a
FACS Aria II (BD). Antibodies used for ﬂow cytometic analysis and cell sorting are
listed in Supplementary Table 2.
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Western blot. Cell extracts were prepared by adding IP Lysis buffer (Thermo
Scientiﬁc) with protease inhibitor cocktail (Sigma). Cell lysates (10 μg) were
separated by 6% SDS-PAGE. Separated proteins were transferred to a PVDF
membrane, and were stained with Notch1, Notch1-ICD antibody (Cell Signaling
Technology), or Actin (Santa Cruz). Immunoblots were visualized using the ECL
PLUS detection kit (Amersham Pharmacia). Quantitative analysis of protein
expression was performed using Image Lab software version 5.2 (Bio-Rad). Anti-
body dilutions are presented in Supplementary Table 2. All uncropped western
blots can be found in Supplementary Fig. 9.
qPCR analysis. Cells were differentiated for the respective days and sorted on a
FACS Aria II. RNA was collected using RNA MiniPrep Plus (Invitrogen) and
quantiﬁed on a NanoDrop (GE Healthcare). Equal amounts of RNA were used for
cDNA synthesis using SuperScript III First-Strand Synthesis System (Life Tech-
nologies). qPCR was conducted using Platinum SYBR Green qPCR SuperMix (Life
Technologies). The reactions were run on a Mastercycler RealPlex Thermal Cycler
(Eppendorf) and the expression levels were calculated by minimal cycle threshold
values (Ct) normalized to the reference expression of RPL13a. The qPCR products
were run on an agarose gel and stained with ethidium bromide to conﬁrm spe-
ciﬁcity of the primers. Primer sequences can be found in Supplementary Table 3.
RNA-Seq data processing and analysis. Total RNA was isolated from the D4 HE,
D5 HE:DLL4+ and HE:DLL4− and CD235a/CD41a−CD34+CD45+ derived from
HE:DLL4+ and HE:DLL4− cells using the RNeasy mini Plus Kit (Qiagen). RNA
purity and integrity was evaluated by capillary electrophoresis on the Bioanalyzer
2100 (Agilent Technologies, Santa Clara, CA). One hundred nanograms of total RNA
was used to prepare sequencing libraries using the TruSeq RNA Sample Preparation
kit (Illumina, San Diego, CA). Final cDNA libraries were quantitated with the Qubit
Fluorometer (Life Technologies, Carlsbad, CA) and multiplexed with eighteen total
indexed libraries per lane. Sequencing was performed using the HiSeq 3000 (Illumina,
San Diego, CA) with a single read of 64 bp and index read of 7 bp.
Base-calling and demultiplexing were completed with the Illumina Genome
Analyzer Casava Software, version 1.8.2. Following quality assessment and ﬁltering
for adapter molecules and other sequencing artifacts, the remaining sequencing reads
were aligned to transcript sequences corresponding to hg19 human genome
annotation. Bowtie v 1.1.2 was used, allowing two mismatches in a 25 bp seed, and
excluding reads with more than 200 alignments70. RSEM v 1.3.0 was used to estimate
isoform or gene relative expression levels in units of 'transcripts per million' (tpm), as
well as posterior mean estimate of the 'expected counts' (the non-normalized absolute
number of reads assigned by RSEM to each isoform/gene)71. R statistical
environment (R core team, 2014) was used at all of the stages of downstream data
analysis. The entire set of libraries was pre-normalized as a pool using median
normalization routine from EBSeq package72. EBSeq with 10 iterations was applied to
call for differential expression. The EBSeq’s default procedure of ﬁltering low-
expressed genes was suppressed by setting the QtrmCut parameter to zero. Genes
with assigned value of Posterior Probability of Differential Expression above 0.95
were preliminary selected. Subsequently, only genes demonstrating the Critical
Coefﬁcent73 value above 1.5 were retained as differentially expressed.
Statistical analysis. Sample sizes were determined by the nature of the experiment
and variability of the output, not by a statistical method. The experiments were not
randomized and the investigators were not blinded to allocation during experi-
ments and outcome assessment. Statistical analysis was performed in PRISM
software. Data obtained from multiple experiments were reported as mean
±standard error. Where appropriate, either a one-way ANOVA or two-way
ANOVA were utilized with a Bonferroni post-hoc test. Differences were considered
signiﬁcant when *p < 0.05, **p < 0.01, or ***p < 0.001.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its Supplementary Information Files or
from the corresponding author upon reasonable request. RNAseq data have been
deposited in the NCBI Gene Expression Omnibus (GEO) database under accession
codes GSE95028 and GSE96815.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95028
https://www.ncbi.nlm.nih.gov/geo/query/=GSE96815
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